Lea Ann Matura1, Jamison Fargo2, Jason S Fritz3, Kerri A Smith3, Anjali Vaidya4, Diane Pinder3, Christine Archer-Chicko3, Harold I Palevsky3, Allan I Pack5, Marilyn S Sommers6, Steven M Kawut7. 1. University of Pennsylvania, School of Nursing, Philadelphia, PA, USA. Electronic address: matura@nursing.upenn.edu. 2. Utah State University, Logan, UT, USA. 3. Perelman School of Medicine of the University of Pennsylvania, Pulmonary, Allergy and Critical Care, Philadelphia, PA, USA. 4. Perelman School of Medicine of the University of Pennsylvania, Division of Cardiovascular Medicine, Philadelphia, PA, USA. 5. Center for Sleep and Respiratory Neurobiology, University of Pennsylvania, Philadelphia, PA, USA. 6. University of Pennsylvania, School of Nursing, Philadelphia, PA, USA. 7. Center for Clinical Epidemiology and Biostatistics, Department of Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA.
Abstract
OBJECTIVE: To determine the feasibility of using slow-paced respiration therapy to treat symptoms in women with pulmonary arterial hypertension (PAH). BACKGROUND: People with PAH report increased dyspnea, fatigue and sleep disturbance that can impair health-related quality of life (HRQOL). METHODS: Ten women with PAH received 8-weeks of daily, 15 min sessions using slow-paced respiration therapy via the RESPeRATE™ device. Participants had baseline and follow up assessments including plasma norepinephrine and interleukin-6 (IL-6), self-report questionnaires to measure dyspnea, fatigue, depressive symptoms, sleep and HRQOL along with 7-day actigraphy and sleep diaries. RESULTS: The mean age was 50 years. Adherence to the intervention was 92%. There was decrease in median IL-6 levels [1.3 ± 0.5 to 1.1 ± 0.4, 95% CI (0.03-0.43)] over the study period. Sleep disturbance decreased, depressive symptoms decreased and HRQOL scores decreased (higher scores indicate worse HRQOL). CONCLUSIONS: In this pilot study, slow-paced respiration therapy is feasible in patients with PAH and may improve symptoms and lower IL-6.
OBJECTIVE: To determine the feasibility of using slow-paced respiration therapy to treat symptoms in women with pulmonary arterial hypertension (PAH). BACKGROUND:People with PAH report increased dyspnea, fatigue and sleep disturbance that can impair health-related quality of life (HRQOL). METHODS: Ten women with PAH received 8-weeks of daily, 15 min sessions using slow-paced respiration therapy via the RESPeRATE™ device. Participants had baseline and follow up assessments including plasma norepinephrine and interleukin-6 (IL-6), self-report questionnaires to measure dyspnea, fatigue, depressive symptoms, sleep and HRQOL along with 7-day actigraphy and sleep diaries. RESULTS: The mean age was 50 years. Adherence to the intervention was 92%. There was decrease in median IL-6 levels [1.3 ± 0.5 to 1.1 ± 0.4, 95% CI (0.03-0.43)] over the study period. Sleep disturbance decreased, depressive symptoms decreased and HRQOL scores decreased (higher scores indicate worse HRQOL). CONCLUSIONS: In this pilot study, slow-paced respiration therapy is feasible in patients with PAH and may improve symptoms and lower IL-6.
Authors: James M Clinton; Christopher J Davis; Mark R Zielinski; Kathryn A Jewett; James M Krueger Journal: J Clin Sleep Med Date: 2011-10-15 Impact factor: 4.062
Authors: Agnieszka Ciarka; Vi Doan; Sonia Velez-Roa; Robert Naeije; Philippe van de Borne Journal: Am J Respir Crit Care Med Date: 2010-03-01 Impact factor: 21.405
Authors: Martica H Hall; Stephen F Smagula; Robert M Boudreau; Hilsa N Ayonayon; Suzanne E Goldman; Tamara B Harris; Barbara L Naydeck; Susan M Rubin; Laura Samuelsson; Suzanne Satterfield; Katie L Stone; Marjolein Visser; Anne B Newman Journal: Sleep Date: 2015-02-01 Impact factor: 5.849
Authors: Bernice Ruo; John S Rumsfeld; Mark A Hlatky; Haiying Liu; Warren S Browner; Mary A Whooley Journal: JAMA Date: 2003-07-09 Impact factor: 56.272
Authors: Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau Journal: Eur Heart J Date: 2009-08-27 Impact factor: 29.983
Authors: Lea Ann Matura; Annette McDonough; Alexandra L Hanlon; Diane L Carroll; Barbara Riegel Journal: Eur J Cardiovasc Nurs Date: 2014-05-27 Impact factor: 3.908
Authors: Robert B Banzett; Carl R O'Donnell; Tegan E Guilfoyle; Mark B Parshall; Richard M Schwartzstein; Paula M Meek; Richard H Gracely; Robert W Lansing Journal: Eur Respir J Date: 2015-03-18 Impact factor: 16.671
Authors: Aaron Shengting Mai; Oliver Zi Hern Lim; Yeung Jek Ho; Gwyneth Kong; Grace En Hui Lim; Cheng Han Ng; Cyrus Ho; Roger Ho; Yinghao Lim; Ivandito Kuntjoro; Edgar Tay; James Yip; Nicholas W S Chew; Ting-Ting Low Journal: Front Med (Lausanne) Date: 2022-02-17